Keytruda-chemo Combo Best for Clearing Tumors in Early TNBC, Latest Trial Data Show

Keytruda-chemo Combo Best for Clearing Tumors in Early TNBC, Latest Trial Data Show
Adding the immunotherapy Keytruda (pembrolizumab) to chemotherapy increases the number of women with early triple-negative breast cancer who clear all signs of cancer, and tends to prolong survival without complications or symptoms, according to the latest results from the KEYNOTE-522 trial. "The data suggest that the improved pathological complete response with pembrolizumab translates into fewer recurrences [the return of cancer],"  Peter Schmid, MD, the medical oncologist who presented the study, said in a press release. The results were shared at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, on Sept. 29, in a presentation titled, "Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)." Triple-negative breast cancer (TNBC) accounts for 15% of breast cancers; it is the most aggressive type of breast cancer and is
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.